Claim · 2018 · event · Stated in source · Supported

Generate Biomedicines' IPO prospectus (26 February 2026) names Gevorg Grigoryan as its Co-Founder and Chief Technology Officer.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Gevorg Grigoryan → co-founded → Generate Biomedicines

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Gevorg Grigoryanco-founded ↓Generate Biomedicines

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2018 · event Records dated 2018 →

Scope and limitsCo-founding and title as the prospectus states them; the prospectus also names Flagship ("Flagship Pioneering") as founder. No complete founder roster is implied.

The evidence 02

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Our Co-Founder and Chief Technology Officer, Dr. Gevorg Grigoryan, Ph.D., is a leading protein scientist”

Location in source Prospectus summary, leadership

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (15 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Flagship Pioneering founded Generate in 2018 as Flagship VL56, Inc., working together with Dr. Gevorg Grigoryan, Ph.D., our founding Chief Technology Officer.”

Location in source Business, "Our Beginnings: Generate and Flagship Pioneering"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (22 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. Gives the founding year by which the record is dated. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. Participation in founding an organisation or research team. Neither sole founding nor legal incorporation is implied.

Date. Founding year as stated in Generate's IPO prospectus of 26 February 2026 ("Flagship Pioneering founded Generate in 2018"); no month or day, and no separate date of Grigoryan's participation, is given.

Record ID aib-co-grigoryan-generate-cofounded